Contact Information

联系方式

地址：陕西省西安市雁塔西路76号西安交通大学医学部病理楼； 邮编710061

Email：jinsong.hu@xjtu.edu.cn

Wechat: 

Work Experience

  1. 中国细胞生物学会第十三届理事会理事（2023年4月-）
  2. 中国细胞生物学学会细胞工程与转基因分会第五届委员（2023年6月-）
  3. 中华医学会医学细胞生物学分会第六届委员会委员 （2018年-）
  4. 中国抗癌协会肿瘤分子医学专业委员会第一届委员（2017年-）
  5. 中国肿瘤防治联盟陕西省淋巴瘤专业委员会第一届委员（2017年-）
  6. 中国多发性骨髓瘤研究联盟理事（2018年-）
  7. 中国抗癌协会第五届血液肿瘤专业委员会骨髓瘤与浆细胞疾病学组委员 （2019年-）
  8. 中国医药教育协会-智能医学专业委员会常委（2019年-）
  9. 中国转化医学联盟细胞生物学分会第一届委员（2019年-）
  10. 陕西省细胞生物学学会第四、五届理事会常务理事（2018年-）

站点计数器

Host Brief Introduction

  1. Michael O'dwyer; Jinsong HU; Improved NK-Based Cell Therapy, 2018-6-14, 美国, WO 2018/104554 A1
  2. 胡劲松; 张丹; 雷莉; 陈萍 ; 卡非佐米在制备用于治疗骨肉瘤药物中的应用, 2020-1-9, 中国, ZL201910995348.1
  3. 胡劲松; 张丹; 雷莉; 陈萍; 贾茜; 硼替佐米在制备用于治疗骨肉瘤药物中的应用, 2020-1-9, 中国, ZL201910995349.6
  4. 胡劲松; 张丹; 雷莉; 王爱英; 一种基于流式细胞术检测NK细胞杀伤活性的方法, 2019-5-20, 中国, ZL201910420306.5
  5. 胡劲松; 郭蕊; 张丹; 雷蕾; 钱宏波; 戴同欣; 一种快速检测离体血样中SARS-CoV-2病毒感染的方法及应用, 2020-3-12, 中国, ZL202010171734.1

Lecture Course

1. 主讲课程

（1）本科生细胞生物学

（2）本科生医学遗传学

（3）研究生医学遗传学（课程负责人）

2. 参编教材

（1）医学细胞生物学（第四版），高教出版社(ISBN 978-7-04-051711-8)（2019年）

（2）医学细胞生物学（第四版），科学出版社(ISBN 978-7-03-061547-3 )（2019年）

（3）医学遗传学（第四版），北医出版社(ISBN 978-7-5659-1780-6)（2018年）

（4）医学遗传学（第四版），人卫出版社(ISBN 978-7-117-26939-1)（2018年）

（5）医学生物学（第九版），人卫出版社(ISBN 978-7-117-26344-3)（2018年）

 

个人信息

胡劲松，（双）博士、教授。

西安交通大学医学部基础医学院细胞生物学与遗传学系、西安交通大学医学部转化医学研究院感染与免疫研究所PI。

西安交通大学医学部基础医学院基础医学实验教学中心副主任。

主要从事恶性血液肿瘤、NK细胞免疫治疗血液肿瘤、抗病毒免疫机制方面的研究。既往研究成功解析了多发性骨髓瘤骨髓微环境特征、蛋白酶体抑制剂耐药以及促成骨发生机制，以及COVID-19单核细胞过度活化的免疫病理机制，相关成果发表在专业领域权威期刊Blood, Leukemia, Stem Cell Research & Therapy,Journal of Leukocyte Biology等。以第一作者或通讯作者共发表论文30余篇，被引用>1200次，H index=16。在NK细胞肿瘤免疫领域获得国际专利授权1项，国家专利授权4项。

主持国家自然科学基金面上项目2项、国际合作项目1项、省部级课题3项。

 

Educational Experience

2008年博士毕业于空军军医大学（原第四军医大学）细胞生物学专业 （导师：陈志南院士）

2012年博士毕业于比利时布鲁塞尔自由大学免疫学与血液学专业（导师：Karin Vanderkerken教授）

2014-2015年爱尔兰国立高威大学医学院博士后(受ONK Therapeutics公司资助）（Michael O'Dwyer教授实验室）

Research Fields

 

1. 多发性骨髓瘤的分子病理机制与耐药机制、骨髓瘤骨病

2. NK细胞肿瘤免疫

3.抗病毒固有免疫

Team Name

2022

  1. Shang Y, Jin Y, Liu H, Ding L, Tong X, Tu H, Zang L, Lin C, Hu J, Zhou F. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. Hematol Oncol. 2022 Apr;40(2):212-222.

2021

  1. Liu R, Shen Y, Hu J, Wang X, Wu D, Zhai M, Bai J, He A. Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma. Front Oncol. 2021 Nov 4;11:731957. doi: 10.3389/fonc.2021.731957.
  2. Wu D, Miao J, Hu J, Li F, Gao D, Chen H, Feng Y, Shen Y, He A. PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib. Front Oncol. 2021 Jul 23;11:684232. doi: 10.3389/fonc.2021.684232.
  3. Shen Y, Feng Y, Li F, Jia Y, Peng Y, Zhao W, Hu J, He A. lncRNA ST3GAL6-AS1 promotes invasion by inhibiting hnRNPA2B1 mediated ST3GAL6 expression in multiple myeloma. Int J Oncol. 2021 Apr;58(4):5.
  4. Wang J, Xu Y, Zhang X, Wang S, Peng Z, Guo J, Jiang H, Liu J, Xie Y, Wang J, Li X, Liao J, Wan C, Yu L, Hu J, Liu B, Liu Z. Leptin correlates with monocytes activation and severe condition in COVID-19 patients. J Leukoc Biol. 2021 Jul;110(1):9-20. （新冠研究，亮点论文+述评）
  5. Lei L, Zhang Y, Jian Q, Lei L, Lv N, Williamson RA, Chen P, Zhang D, Hu J. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways. Exp Physiol. 2021 Feb;106(2):438-449.
  6. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, Qian H, Dai T, Zhang T, Lai Y, Wang J, Liu Z, Chen T, He A, O'Dwyer M, Hu J. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2021 Jan;109(1):13-22. （新冠研究，亮点论文+述评）

2020

  1. Zhang D, De Veirman K, Fan R, Jian Q, Zhang Y, Lei L, Evans H, Wang Y, Lei L, Wang B, Williamson RA, Chantry A, He P, Li A, De Raeve H, Vanderkerken K, He A, Hu J. ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. Stem Cell Res Ther. 2020 Nov 30;11(1):516.
  2. Teng R, Wang Y, Lv N, Zhang D, Williamson RA, Lei L, Chen P, Lei L, Wang B, Fu J, Liu X, He A, O'Dwyer M, Hu J. Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. J Immunol Res. 2020 Jun 19;2020:4598476.
  3. Yang X, Dai T, Zhou X, Qian H, Guo R, Lei L, Zhang X, Zhang D, Shi L, Cheng Y, Hu J, Guo Y, Zhang B. Naturally activated adaptive immunity in COVID-19 patients. J Cell Mol Med. 2020 Nov;24(21):12457-12463.
  4. Lei L, Qian H, Yang X, Zhang X, Zhang D, Dai T, Guo R, Shi L, Cheng Y, Zhang B, Zhou X, Hu J, Guo Y. The phenotypic changes of gamma-delta T cells in COVID-19 patients. J Cell Mol Med. 2020 Oct;24(19):11603-11606.
  5. Zhang D, Teng R, Lv N, Lei L, Wang Y, Williamson RA, Chen P, Gao P, O'Dwyer M, Li A, Hu J. A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. J Clin Lab Anal. 2020 Dec;34(12):e23519.
  6. Zhang D, Teng R, Lv N, Lei L, Wang Y, Williamson RA, Chen P, Gao P, O'Dwyer M, Li A, Hu J. A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. J Clin Lab Anal. 2020 Dec;34(12):e23519.
  7. Wang H, Lei L, Hu J, Li Y. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. Exp Physiol. 2020 Jul;105(7):1151-1158.
  8. Peng Y, Li F, Zhang P, Wang X, Shen Y, Feng Y, Jia Y, Zhang R, Hu J, He A. IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition. Life Sci. 2020 May 15;249:117503.
  9. Huang L, Wang Y, Bai J, Yang Y, Wang F, Feng Y, Zhang R, Li F, Zhang P, Lv N, Lei L, Hu J, He A. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. Cell Stress Chaperones. 2020 Mar;25(2):357-367.
  10. Huang LJ, Shen Y, Bai J, Wang FX, Feng YD, Chen HL, Peng Y, Zhang R, Li FM, Zhang PH, Lei XR, Xue F, Ma YP, Hu JS, He AL. High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma. Acta Haematol. 2020;143(3):279-288.
  11. Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M. The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. Cancer Immunol Immunother. 2020 Mar;69(3):421-434.

2019

  1. Jia X, Zhao Q, Zhang Y, Dong Y, Lei L, Williamson RA, Lei Y, Tan X, Zhang D, Hu J. Identification of a Five-CpG Signature with Diagnostic Value in Thyroid Cancer. J Comput Biol. 2019 Dec;26(12):1409-1417.
  2. Zhang D, Cui G, Sun C, Lei L, Lei L, Williamson RA, Wang Y, Zhang J, Chen P, Wang A, Fan R, Han S, Wang Y, Hu J. Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-b axis. Biochem Biophys Res Commun. 2019 Apr 30;512(2):360-366.

2018 - 2010 （selected）

  1. Zhu M, Tian Y, Zhang H, Ma X, Shang B, Zhang J, Jiao Y, Zhang Y, Hu J, Wang Y. Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress. Life Sci. 2018 Mar 15;197:40-45.
  2. Hu J, Van Valckenborgh E, Dehui X, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides D, Hart CP, Vanderkerken K. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther. 2013;12(9):1763-1773.  
  3. Xu D, Hu J, Xu S, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia. 2012;26(6):1402-5.      
  4. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, hompson B, Maiso P, Sun JD, Hart CP, Roccaro AM, acco A, Ngo HT, Lin CP, Kung AL, Carrasco DR, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features. Blood. 2012;119(24):5782-94.    
  5. Xu D, Hu J, Bruyne ED, Menu E, Schots R, Vanderkerken K, Van Valckenborgh E. Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun. 2012;428(4):518-24.     
  6. Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012;26(12):2546-9.
  7. Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech. 2012;5(6):763-71.            
  8. Hu J, Dang N, Menu E, De Bryune E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood. 2012;119(3):826-37.    
  9. Hu J, Dang N, Song T, Vanderkerken K. Mcl-1 reduction due to caspase-dependent cleavage during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2011;286(44):le24.  
  10. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood. 2010;116(9):1524-7.